glp-1 eligibility criteria Does CMS Know What It Is Doing With Its Obesity Coverage Pilot? CMS's new GLP-1 Bridge program expands Medicare access to obesity drugs but raises concerns about cost, supply and implementation What to Know About the
Description
Both drugs have been on the FDAs drug shortage list since 2022

Merck is investing heavily in vaccine and biologics manufacturing, including US-based expansions

Diabetologia (2009) 52:158998

At approved weight-loss doses, caloric intake typically decreases in a consistent and measurable way

Two patients losing the same percentage of body weight may have very different risk profiles: Risk is behavioural, not automatic

Singh S, Wright EE Jr, Kwan AY, Thompson JC, Syed IA, Korol EE, et al
